Aflibercept biosimilar (Zein Bioteccnology)

阿柏西普生物类似药（植恩生物）

Report date: 2022/03/23 14:23:35

Base Information

Drug NameAflibercept biosimilar (Zein Bioteccnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedema
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZein Bioteccnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZein Bioteccnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedema
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A